440 related articles for article (PubMed ID: 15992564)
1. Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism.
Kiefer F; Jahn H; Otte C; Demiralay C; Wolf K; Wiedemann K
J Psychiatr Res; 2005 Sep; 39(5):545-51. PubMed ID: 15992564
[TBL] [Abstract][Full Text] [Related]
2. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.
Morley KC; Teesson M; Reid SC; Sannibale C; Thomson C; Phung N; Weltman M; Bell JR; Richardson K; Haber PS
Addiction; 2006 Oct; 101(10):1451-62. PubMed ID: 16968347
[TBL] [Abstract][Full Text] [Related]
3. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
Richardson K; Baillie A; Reid S; Morley K; Teesson M; Sannibale C; Weltman M; Haber P
Addiction; 2008 Jun; 103(6):953-9. PubMed ID: 18482418
[TBL] [Abstract][Full Text] [Related]
4. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
Rösner S; Leucht S; Lehert P; Soyka M
J Psychopharmacol; 2008 Jan; 22(1):11-23. PubMed ID: 18187529
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological relapse prevention of alcoholism: clinical predictors of outcome.
Kiefer F; Helwig H; Tarnaske T; Otte C; Jahn H; Wiedemann K
Eur Addict Res; 2005; 11(2):83-91. PubMed ID: 15785069
[TBL] [Abstract][Full Text] [Related]
6. Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment?
Kiefer F; Jahn H; Otte C; Naber D; Wiedemann K
Biol Psychiatry; 2006 Jul; 60(1):74-6. PubMed ID: 16483549
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials.
Snyder JL; Bowers TG
Am J Drug Alcohol Abuse; 2008; 34(4):449-61. PubMed ID: 18584575
[TBL] [Abstract][Full Text] [Related]
8. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy.
Feeney GF; Connor JP; Young RM; Tucker J; McPherson A
Alcohol Alcohol; 2006; 41(3):321-7. PubMed ID: 16467406
[TBL] [Abstract][Full Text] [Related]
9. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.
Mann K; Lemenager T; Hoffmann S; Reinhard I; Hermann D; Batra A; Berner M; Wodarz N; Heinz A; Smolka MN; Zimmermann US; Wellek S; Kiefer F; Anton RF;
Addict Biol; 2013 Nov; 18(6):937-46. PubMed ID: 23231446
[TBL] [Abstract][Full Text] [Related]
10. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment.
Rubio G; Jiménez-Arriero MA; Ponce G; Palomo T
Alcohol Alcohol; 2001; 36(5):419-25. PubMed ID: 11524308
[TBL] [Abstract][Full Text] [Related]
11. A neuroendocrinological hypothesis on gender effects of naltrexone in relapse prevention treatment.
Kiefer F; Jahn H; Wiedemann K
Pharmacopsychiatry; 2005 Jul; 38(4):184-6. PubMed ID: 16025425
[TBL] [Abstract][Full Text] [Related]
12. Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective.
Soyka M; Chick J
Am J Addict; 2003; 12(s1):s69-s80. PubMed ID: 14972781
[TBL] [Abstract][Full Text] [Related]
13. [The pharmacologic treatment of the alcohol dependence].
Castro LA; Baltieri DA
Braz J Psychiatry; 2004 May; 26 Suppl 1():S43-6. PubMed ID: 15729444
[TBL] [Abstract][Full Text] [Related]
14. Results from two pharmacotherapy trials show alcoholic smokers were more severely alcohol dependent but less prone to relapse than alcoholic non-smokers.
Schmidt LG; Smolka MN
Alcohol Alcohol; 2007; 42(3):241-6. PubMed ID: 17526634
[TBL] [Abstract][Full Text] [Related]
15. [Acamprosate and naltrexone: similar efficacy for relapse].
Saitz R
Rev Med Suisse; 2014 Dec; 10(455):2437. PubMed ID: 25752019
[No Abstract] [Full Text] [Related]
16. The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics.
Ooteman W; Koeter MW; Verheul R; Schippers GM; van den Brink W
Eur Neuropsychopharmacol; 2007 Jul; 17(8):558-66. PubMed ID: 17379484
[TBL] [Abstract][Full Text] [Related]
17. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Anton RF; O'Malley SS; Ciraulo DA; Cisler RA; Couper D; Donovan DM; Gastfriend DR; Hosking JD; Johnson BA; LoCastro JS; Longabaugh R; Mason BJ; Mattson ME; Miller WR; Pettinati HM; Randall CL; Swift R; Weiss RD; Williams LD; Zweben A;
JAMA; 2006 May; 295(17):2003-17. PubMed ID: 16670409
[TBL] [Abstract][Full Text] [Related]
18. Clinical predictors of outcome from an Australian pharmacological relapse prevention trial.
Morley KC; Teesson M; Sannibale C; Baillie A; Haber PS
Alcohol Alcohol; 2010; 45(6):520-6. PubMed ID: 20952764
[TBL] [Abstract][Full Text] [Related]
19. Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland.
Buri C; Moggi F; Giovanoli A; Strik W
Alcohol Alcohol; 2007; 42(4):333-9. PubMed ID: 17517820
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological treatment of alcohol dependence: a review of the evidence.
Garbutt JC; West SL; Carey TS; Lohr KN; Crews FT
JAMA; 1999 Apr; 281(14):1318-25. PubMed ID: 10208148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
